Blockchain
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr. Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. With expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADC), nucleoside/nucleotide drugs, and oligonucleotide drugs (such as RNAi). Additionally, Medicilon has made significant advancements in PROTAC technology and enhanced its BSL-2 laboratory facility.
With the growing pharmaceutical industry and the widespread adoption of artificial intelligence, the market potential for drug discovery is enormous. The addition of Dr. Liu Jian, a seasoned pharmaceutical research scientist, will empower Medicilon Drug Discovery division to revolutionize drug discovery model and bring new imagination to drug discovery.
Dr. Liu Jian obtained his Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA), he subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania. In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA. In 2019, he was awarded the “Outstanding 50 Asian American in Business ” by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New jersey.
With over 20 years of experience in innovative drug development, Dr. Liu Jian has led the team to invent 10 preclinical candidates (PCCs), which have entered Phase I, II, and III clinical trials. He has filed over 72 patent applications, with 21 patents already granted. Dr. Liu Jian also possesses profound academic achievements, having published a total of 47 articles in international academic journals and serving as a reviewer for several international academic journals.
Dr. Liu Jian joined the industry in 2001 and has worked for Merck for nearly 20 years. He has led the R&D of novel small molecule drugs for various diseases, including osteoporosis, obesity, diabetes, cardiovascular disease, cancer, immune disease, antiviral and antibacterial, and pain. Throughout his career, he progressed from Senior Research Chemist to Principal Scientist and External Discovery Chemistry Lead, receiving the “Merck Excellence Award” four times. He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI), leading the development of new drugs for cancer, immune diseases, osteoarthritis, and neurodegenerative diseases. Recently, he became the CEO of Silexon AI, responsible for building the company’s artificial intelligence platform and empowering innovative drug research.
Dr. Liu Jian expressed his honor to be part of Medicilon as President of Drug Discovery Division. Medicilon is known for establishing a comprehensive pharmaceutical preclinical research and development service platform in China and cultivated for 19 years. It has prioritized global cutting-edge technologies and fostered technological innovation. Moving forward, Dr. Liu aims to lead the Drug Discovery Division in efficient and high-quality new drug development. This includes establishing and enhancing various technical platforms for innovative drug research such as AIDD and structural biology, peptide and cyclic peptide drug development, synthetic biology, and nuclear medicine development, realizing Medicilon one-stop service experiment from target research recommendation to IND application, we could empower the discovery of more innovative drugs.
Dr. Chen Chunlin, the Founder and CEO of Medicilon, said, “Welcome Dr. Liu Jian to join Medicilon. We believe that his extensive academic background, outstanding leadership and rich R&D experience will bring Medicilon more professional and cutting-edge innovative drug development technology , as well as advanced industry insights and strategic guidance crucial to Medicilon to next stage of development.
ZettaBlock, a leading provider of blockchain solutions, has recently announced a significant enhancement to its offerings with the addition of blockchain data services. This development marks a strategic move aimed at bolstering ZettaBlock’s capabilities and further solidifying its position in the blockchain industry.
By integrating blockchain data services into its portfolio, ZettaBlock seeks to address the growing demand for comprehensive and reliable data solutions within the blockchain ecosystem. The new offering will enable clients to access a wealth of blockchain data, empowering them to make informed decisions and derive valuable insights from the vast amount of information available on various blockchain networks.
ZettaBlock’s decision to expand its services comes at a time when the importance of blockchain data analytics is increasingly recognized across industries. With blockchain technology continuing to gain traction and adoption worldwide, the ability to effectively harness and analyze blockchain data has become crucial for businesses and organizations seeking to unlock new opportunities and drive innovation.
Through its blockchain data services, ZettaBlock aims to cater to the diverse needs of its clients, providing them with access to real-time and historical data from a wide range of blockchain networks. This includes transaction data, smart contract metrics, network activity, and more, allowing users to gain deeper insights into blockchain transactions and activities.
The addition of blockchain data services represents a significant milestone for ZettaBlock, underscoring the company’s commitment to delivering cutting-edge solutions that meet the evolving needs of the blockchain industry. As businesses increasingly recognize the value of blockchain data in driving decision-making and enhancing operations, ZettaBlock’s comprehensive data services are poised to play a key role in shaping the future of blockchain analytics.
Source: cryptonewsz.com
The post ZettaBlock announces the addition of blockchain data appeared first on HIPTHER Alerts.
Hong Kong has entered the cryptocurrency ETF market with the debut of its first spot cryptocurrency exchange-traded funds (ETFs) on Tuesday, signaling the city’s ambition to compete with the US in the rapidly growing sector.
The launch, led by the Hong Kong units of three mainland Chinese asset managers — Bosera Asset Management, Harvest Global Investments, and China Asset Management — saw the introduction of two ETFs each tracking bitcoin and ether prices. Bosera’s funds were launched in collaboration with HashKey Capital.
On their debut, the three bitcoin ETFs closed between 1.5% and 1.8% higher, while the ether ETFs experienced slight losses of between 0.5% and 0.8%. Despite this, total trading turnover for all six ETFs, which included trading in US dollars, Hong Kong dollars, and renminbi, reached approximately HK$99.5 million (US$12.7 million). In comparison, US-based funds saw turnover exceeding $4 billion on their first trading day.
The move marks Hong Kong’s commitment to becoming a significant player in the cryptocurrency space, following its announcement in 2022 amid pandemic restrictions and increased Chinese oversight. Joseph Chan, Hong Kong’s under-secretary for financial services and the treasury, emphasized the city’s leading position in Asia’s crypto asset development during the ETF listing ceremony.
Prior to this, CSOP Asset Management had launched Hong Kong’s first bitcoin and ether futures ETFs in late 2022, following the publication of rules for spot ETFs by the Securities and Futures Commission in December.
In January, the US Securities and Exchange Commission approved the country’s first spot bitcoin ETFs, which have since attracted significant assets under management and net inflows. Robert Zhan, director of risk consulting at KPMG China, remains optimistic about the potential of the Hong Kong funds, despite current market sentiments and relatively flat prices of bitcoin and ether leading up to the launch.
The launch of crypto-linked funds by major Chinese asset managers has generated excitement within the industry, despite China’s strict cryptocurrency regulations. Donald Day, COO of Hong Kong-based digital asset exchange VDX, believes the new funds will cater to active investors unable or unwilling to trade during US hours.
Source: ft.com
The post Hong Kong joins global crypto ETF race appeared first on HIPTHER Alerts.
Crypto News Flash reports that LBank Labs has announced a strategic investment in Bedrock to revolutionize blockchain staking. This partnership signifies a significant step forward in enhancing the efficiency and accessibility of blockchain staking solutions.
LBank Labs’ investment in Bedrock underscores its commitment to driving innovation in the blockchain space and exploring new opportunities to empower users with cutting-edge staking technologies. By leveraging Bedrock’s expertise and solutions, LBank Labs aims to enhance its staking platform and offer users a seamless and rewarding staking experience.
The collaboration between LBank Labs and Bedrock holds promise for unlocking new possibilities in blockchain staking and expanding the adoption of staking services among cryptocurrency enthusiasts. Through joint efforts, both companies aim to address key challenges in the staking ecosystem and drive greater participation in blockchain networks.
Overall, the strategic investment by LBank Labs in Bedrock underscores the growing momentum behind blockchain staking and highlights the industry’s commitment to fostering innovation and advancing the capabilities of decentralized networks. As staking continues to play a crucial role in securing blockchain networks and incentivizing participation, collaborations like this are poised to shape the future of the staking landscape.
Source: crypto-news-flash.com
The post LBank Labs Announces Strategic Investment in Bedrock to Revolutionize Blockchain Staking appeared first on HIPTHER Alerts.
-
Blockchain6 days agoExisting Blockchains Can’t Adopt Post-Quantum Cryptography Without Significant User Impact, Says Johann Polecsak
-
Blockchain Press Releases2 days agoCoinRoutes partners with Coinbase International Exchange to improve institutional access to perpetual futures
-
Blockchain Press Releases3 days agoBosera HashKey Bitcoin and Ether Spot ETFs Officially Launch on HKEX with Two-Way Investment Flexibility
-
Blockchain3 days ago
RFK Jr.’s blockchain idea, Ethereum ETF approval in question, Bitcoin’s unlikely bull run | Weekly Recap
-
Blockchain5 hours agoMeritrust Credit Union Joins Metal Blockchain’s Banking Innovation Program
-
Blockchain2 days ago
Cryptocurrency market sees decline as Bitcoin and Ethereum slip
-
Blockchain Press Releases2 days agoKuCoin Campus Survey Reveals: 88% of Participants Eager to Build Careers in Blockchain
-
Blockchain6 days ago
FBI warning against crypto money transmitters ‘appears’ to be aimed at mixers
